Clearside Biomedical (NASDAQ:CLSD) Issues Quarterly Earnings Results

Clearside Biomedical (NASDAQ:CLSD) issued its quarterly earnings results on Thursday. The company reported ($0.10) EPS for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.03, Zacks reports.

Clearside Biomedical Trading Up 1.0 %

CLSD stock traded up $0.01 on Thursday, hitting $1.03. 151,241 shares of the company’s stock traded hands, compared to its average volume of 356,917. The stock has a market cap of $78.12 million, a price-to-earnings ratio of -2.29 and a beta of 2.10. Clearside Biomedical has a 1-year low of $0.77 and a 1-year high of $1.76. The stock has a fifty day moving average of $0.96 and a 200-day moving average of $1.05.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the stock. HC Wainwright reissued a “buy” rating and issued a $6.00 price objective on shares of Clearside Biomedical in a research report on Thursday, March 6th. StockNews.com cut shares of Clearside Biomedical from a “hold” rating to a “sell” rating in a report on Tuesday, March 18th. Finally, Needham & Company LLC restated a “buy” rating and set a $6.00 price objective on shares of Clearside Biomedical in a research note on Thursday, March 6th. One research analyst has rated the stock with a sell rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $5.75.

About Clearside Biomedical

Clearside Biomedical, Inc, a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD.